Real Estate. 3QFY19E Results Preview. 11 Jan Parikshit D Kandpal, CFA

Similar documents
Real Estate. 4QFY17E Results Preview. 13 Apr Parikshit D Kandpal

Agrochemicals. 3QFY18E Results Preview 09 JAN Basanth Patil

Capital Goods. 3QFY18E Results Preview. 10 Jan Sujit Jain

Agriculture. 4QFY18E Results Preview 13 APR Madhukar Ladha

Construction. 4QFY18E Results Preview 14 APR Parikshit D Kandpal

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Healty cigarette-driven growth

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

Crompton Greaves Consumer Electricals

Crompton Greaves Consumer Electricals

BLS International Services

Construction & Infra. 1QFY19E Results Preview 10 JUL Parikshit D Kandpal

Neuland Labs BUY RESULTS REVIEW 1QFY19 12 AUG 2018

J. Kumar Infraprojects

Gulf Oil Lubricants BUY RESULTS REVIEW 1QFY19 09 AUG Key highlights

Multi Commodity Exchange

Navin Fluorine International

Intellect Design Arena

ICICI Prudential Life

Oil & Gas. 4QFY17E Results Preview. 13 Apr Deepak Kolhe

Max Financial. Improving margins! BUY RESULTS REVIEW 4QFY18 30 MAY Highlights of the quarter

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

PI Industries BUY RESULTS REVIEW 1QFY19 07 AUG Highlights of the quarter

Near-term pressure, but long-term outlook positive

Brigade Enterprises. Stable performance BUY RESULTS REVIEW 2QFY19 14 NOV 2018

NRB Bearings. Strong Show BUY RESULTS REVIEW 4QFY18 23 MAY Highlights of the quarter

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Pre-sales pickup key trigger

Discounting $45/bbl of realisation

Torrent Pharma BUY RESULTS REVIEW 1QFY18 01 AUG 2017

Alkem Labs BUY RESULTS REVIEW 1QFY19 11 AUG story remains on-track. Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS).

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Sun Pharma BUY RESULTS REVIEW 1QFY19 16 AUG 2018

Central Depository Services

Chemicals and Fertilisers

J. Kumar Infraprojects

Central Depository Services

Mahanagar Gas BUY RESULTS REVIEW 1QFY19 01 AUG Highlights of the quarter. CMP (as on 1 Aug 2018) Rs 947 Target Price Rs 1,292

Carborundum Universal

Vinati Organics BUY RESULTS REVIEW 2QFY19 29 OCT INDUSTRY CHEMICALS CMP (as on 29 Oct 2018) Rs 1,408 Target Price Rs 1,700

Central Depository Services

Hindustan Unilever BUY RESULTS REVIEW 4QFY17 18 MAY 2017

Kalpataru Power Transmission

PSP Projects. Marginal miss BUY RESULTS REVIEW 1QFY19 10 AUG 2018

Music Broadcast. In-line but muted BUY RESULTS REVIEW 2QFY19 26 OCT Key highlights. CMP (as on 26 Oct 2018) Rs 328 Target Price Rs 387

Dilip Buildcon. Strong comeback BUY RESULT REVIEW 1QFY19 16 AUG Highlights of the quarter. CMP (as on 16 Aug 2018) Rs 847 Target Price Rs 1,434

Maruti Suzuki. A Trough Quarter BUY RESULTS REVIEW 3QFY19 25 JAN CMP(as on 25 Jan 2019) Rs 6,516 Target Price Rs 7,400

Jubilant Life Sciences

Hindustan Petroleum Corporation

Alkem Labs BUY RESULTS REVIEW 3QFY19 09 FEB CMP (as on 08 Feb 2019) Rs 1,904 Target Price Rs 2,340. Highlights of the quarter

Geared for version 3.0

Residential recovery awaited

Exide Industries BUY RESULTS REVIEW 4QFY18 08 MAY Highlights of the quarter. CMP (as on 08 May 2018) Rs 268 Target Price Rs 298

Radico Khaitan BUY RESULTS REVIEW 3QFY19 24 JAN 2019

Ambuja Cement. Realisations-driven beat SELL RESULTS REVIEW 2QCY17 25 JUL Highlights of the quarter

Strong volumes, offset by costs

Dr. Reddy s Labs. Misery continues SELL RESULTS REVIEW 1QFY18 28 JUL 2017

Crompton Greaves Consumer Electricals

Bharti Infratel BUY RESULT REVIEW 3QFY19 25 JAN 2019

Margin boost through non-core book

Cement, Metals & Mining

Hindustan Petroleum Corporation

Pharmaceuticals. 2QFY19 Results Preview. 10 Oct Amey Chalke

Reliance Industries. Timing is everything BUY COMPANY UPDATE 1 OCT 2014

Tata Steel. JV comes to fruition BUY COMPANY UPDATE 21 SEP Other key highlights. CMP (as on 20 Sep 17) Rs 688 Target Price Rs 818

Weak show, DCCDL key trigger

Hero MotoCorp BUY RESULTS REVIEW 2QFY19 16 OCT CMP (as on 16 Oct 2018) Rs 2,898 Target Price Rs 3,602. Highlights of the quarter

Dishman Carbogen Amcis

Bajaj Auto BUY RESULTS REVIEW 1QFY18 21 JUL Highlights of the quarter

Weak quarter but well placed

Outperformance continues

Bharat Petroleum Corporation

IRB Infrastructure Developers

Multi Commodity Exchange

Subros BUY RESULTS REVIEW 2QFY19 30 OCT CMP (as on 29 Oct 2018) Rs 268 TP Rs 435. Key highlights

Sonata Software. On growth path BUY RESULTS REVIEW 1QFY18 16 AUG Highlights of the quarter

NIIT Technologies. NEUTRAL Higher capex weighing on FCF RESULTS REVIEW 2QFY15 16 OCT 2014

JBM Auto. Ready to take off BUY RESULTS REVIEW 1QFY19 07 AUG Key highlights

Weak numbers in peak quarter

ITC BUY RESULTS REVIEW 1QFY19 27 JUL 2018

Insecticides India BUY RESULTS REVIEW 4QFY17 30 MAY 2017

IRB Infrastructure Developers

Navin Fluorine International

Lupin BUY COMPANY UPDATE 12 SEP 2013

Mphasis. Growth drivers intact BUY RESULTS REVIEW 3QFY19 25 JAN 2019

FIRSTSOURCE SOLUTIONS LTD.

Emami NEUTRAL RESULTS REVIEW 4QFY15 14 MAY 2015

Bajaj Auto NEUTRAL RESULTS REVIEW 2QFY16 23 OCT Key highlights. CMP (as on 23 Oct 2015) Rs 2,514 Target Price Rs 2,720

Coromandel International

Coal India. Tough times BUY COMPANY UPDATE 22 AUG CMP (as on 21 Aug 17) Rs 238 Target Price Rs 300

Cyient. Good show, priced in NEUTRAL RESULTS REVIEW 4QFY17 21 APRIL Highlights of the quarter

Autos. 4QFY18E Results Preview. 12 Apr Abhishek Jain

V-Guard BUY RESULTS REVIEW 3QFY19 02 FEB 2019

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

Suprajit Engineering. Synergies to accrue BUY COMPANY UPDATE 16 SEP 2016

SBI Life Insurance Company

Thangamayil BUY RESULTS REVIEW 2QFY19 15 NOV 2018

Brigade Enterprises BUY RESULTS REVIEW 2QFY16 03 NOV Highlights of the quarter. CMP (as on 03 Nov 2015) Rs 162 Target Price Rs 210

Bharat Forge. Cyclical headwinds persist but structural story intact BUY COMPANY UPDATE 9 DEC Key takeaways

1%+ RoA on the horizon

Transcription:

Real Estate Results Preview 11 Jan 2019 Parikshit D Kandpal, CFA parikshit.kandpal@hdfcsec.com +91-22-6171 7317 Kunal Bhandari kunal.bhandari@hdfcsec.com +91-22-6639 3035

FY14 4QFY14 1QFY15 2QFY15 FY15 4QFY15 1QFY16 2QFY16 FY16 4QFY16 1QFY17 2QFY17 FY17 4QFY17 1QFY18 2QFY18 FY18 4QFY18 1QFY19 2QFY19 2QFY14 FY14 4QFY14 1QFY15 2QFY15 FY15 4QFY15 1QFY16 2QFY16 FY16 4QFY16 1QFY17 2QFY17 FY17 4QFY17 1QFY18 2QFY18 FY18 4QFY18 1QFY19 Gradual recovery Over last 1-Yr, Nifty Realty index has corrected 36%. Large part of this fall has been on back of tepid real estate demand, weak pricing power and higher interest rate. The fall was further accentuated by NBFC liquidity issues and its impact on overall lending to real estate sector. Negatives: NBFC liquidity issues in the interim has been well handled by financial ecosystem though over long term sector will become more regulated. Easy liquidity access to developers will now be challenging and we would see some defaults as repayment moratorium ends. Ever greening will now be thing of past. Positives: Likely reduction in GST rate of 12%, extension of CLSS scheme and sales activation (freebies, waivers on registration, stamp duty etc) will aid absorption. Affordable luxury projects will be key drivers of volume as demand is largely end user driven now. Sobha, Prestige, Brigade, Kolte are well placed. DLF to Oberoi are worst impacted. Amongst our coverage universe we expect strong results across companies viz. DLF/Oberoi/Kolte/Prestige/Brigade & Sobha. IND-AS 115 is reversals is aiding financial performance. During, our coverage universe aggregate Revenue/EBIDTA will grow 27.2/7.7 YoY. PAT (ex DLF) will grow by 36.0% YoY whereas DLF will post a profit of Rs 3.7bn vs a loss of 4.2bn in FY18. Change in rating, Top Picks: No Change in Rating. Minor TP changes to factor in Dec-20E valuation roll over. Top Picks: Oberoi realty & Prestige estates. Residential: Affordable Housing Drives Volumes Recovery 100 80 60 40 20 - Commercial Office Absorption Healthy, Vacancy Stable 15.0 10.0 5.0 - Volumes (mn sqft) Inventory (months) - RHS Absorption (mn sqft) Supply (mn sqft) Vacancy - RHS Source: HDFC sec Inst Research, Commercial - Cushman Wakefield, Residential - Liases Foras. Commercial/Residential data takes into account Top 6 Indian Cities of MMR, NCR, Bengaluru, Chennai, Pune and Hyderabad - 60 50 40 30 20 10 0 25.0 20.0 15.0 10.0 5.0 2

Growth Recovery COMPANY OUTLOOK WHAT S LIKELY KEY MONITORABLES DLF Revenue (under project completion) to grow 13.3% YoY EBIDTA margins to remain flat QoQ at 30.9% (prior period not comparable due to DCCDL contributing to EBITDA in FY18) Net profit of Rs 3.7bn vs a adjusted loss of Rs 4.2bn in FY18 Sales momentum in residential segment Update on high value inventory in Phase V Update on QIP timeline Oberoi Realty We expect strong 87.6% YoY revenue growth EBIDTA margins to contract 870bps YoY to 45.4% as residential contribution increases Net profit to increase 28.9% YoY to Rs 1.6bn Update on project planned in Thane Update on timeline for Commerz -III Momentum in Sky City and 360 West Prestige Estates We expect 9.7% YoY growth in revenue EBIDTA margins to increase by 90.7bps YoY to 20.9% Net profit to increase 22.6% YoY Pace of new launches Outlook on debt levels Update on unsold inventory Sobha We estimate 27.8% YoY growth in revenue EBIDTA margins may be decline 176.8bps YoY to 18.1% Net profit to grow 20.9% YoY Update on APMC project Debt levels and pace of land monetization Outlook on commercial capex 3

Growth recovery COMPANY OUTLOOK WHAT S LIKELY KEY MONITORABLES Brigade Enterprises We expect revenue growth of 81.1% YoY Blended EBIDTA margins may contract 1,026bps to 27.3% QoQ Net Profit to grow 71.2% YoY Outlook on debt levels and asset capex Update on realization trends New launches and pre-sales Revenue to grow 31.2% YoY Update on planned launches Kolte Patil EBIDTA margin contraction by 480bps YoY to 21.1% Net profit to grow 76.3% YoY Update on Mumbai and Bengaluru targets 4

Financial summary COMPANY NET SALES (Rs bn) EBITDA (Rs bn) EBITDA Margin APAT (Rs bn) Adj. EPS (Rs/sh) QoQ YoY QoQ YoY DLF 19.19 (10.3) 13.3 5.92 (10.2) (15.5) 30.9 4.1 (1,054.4) 3.72 (0.8) (188.9) 2.1 2.1 (2.3) Oberoi Realty 6.68 12.9 87.6 3.03 2.5 57.4 45.4 (458.5) (870.3) 1.55 (27.5) 28.9 4.3 5.9 3.3 Prestige Estates 14.0 5.5 9.7 2.92 (20.3) 14.7 20.9 (678.0) 90.7 1.10 13.3 22.6 2.9 2.6 2.4 Sobha Limited 8.85 34.3 27.8 1.60 14.2 16.5 18.1 (318.0) (176.8) 0.65 23.2 20.9 6.8 5.5 5.6 Brigade Enterprises 7.68 (7.1) 81.1 2.10 (4.2) 31.6 27.3 80.4 (1,026.0) 0.84 22.4 71.2 6.1 5.0 3.6 Kolte-Patil Developers 3.50 66.0 31.2 0.74 74.1 6.9 21.1 98.6 (480.3) 0.49 386.3 76.3 6.5 1.3 3.7 Aggregate 59.85 4.1 27.2 16.31 (5.3) 7.7 27.2 (271.6) (493.6) 8.34 2.2 (1,165.7) Source: Company, HDFC sec Inst Research QoQ YoY QoQ YoY 2Q FY19 FY18 5

Financial summary Change in TP Company Old Rating New Rating Previous TP (Rs/sh) New TP (Rs/sh) DLF BUY BUY 253 267 Oberoi Realty BUY BUY 552 543 Prestige Estates BUY BUY 309 314 Sobha Limited BUY BUY 630 620 Brigade Enterprises BUY BUY 306 303 Kolte-Patil Developers BUY BUY 314 316 Rating Change Comments Source: HDFC sec Inst Research 6

Financial summary Change in Estimates Oberoi Limited (C) Old New % Revenues (Rs mn) 28,767 28,767 - EBIDTA(Rs mn) 14,027 14,027 - EBIDTA Margins 48.8 48.8 - We have reduced the associate profits from the Worli Project as revenue recognition expected to be postponed to FY20E APAT (Rs mn) 12,157 9,310 (23.4) Source: Company, HDFC sec Inst Research Prestige Estates (C) Old New % Revenues (Rs mn) 50,316 50,316 0.0 EBIDTA(Rs mn) 10,278 12,172 18.4 EBIDTA Margins 20.4 24.2-376.5 EBITDA margins to be higher on account of treatment of period costs under IND AS 115 for re-recognition of reversed sales APAT (Rs mn) 3,164 3,727 17.8 Source: Company, HDFC sec Inst Research 7

Peer set comparison COMPANY MCap (Rs bn) CMP (Rs) Source: Company, HDFC sec Inst Research RECO TP (Rs) Adj. EPS (Rs/sh) P/E (x) EV/EBITDA (x) ROE FY18 FY20E FY18 FY20E FY18 FY20E FY18 FY20E DLF 326 183 BUY 267 7.4 8.9 9.3 24.8 20.5 19.6 21.2 21.4 21.8 3.7 4.3 4.4 Oberoi Realty 167 460 BUY 543 25.6 36.4 41.2 18.0 12.6 11.2 11.9 9.8 8.9 13.1 15.0 15.2 Prestige Estates 83 221 BUY 314 9.9 9.3 11.2 22.2 23.8 19.8 11.7 12.8 11.0 12.2 9.5 11.0 Sobha Limited 45 476 BUY 620 26.2 31.5 31.0 18.2 15.1 15.4 11.4 9.9 9.9 8.7 9.8 8.9 Brigade Enterprises 28 206 BUY 303 24.3 21.7 19.0 8.5 9.5 10.8 7.2 7.6 7.7 13.6 10.9 8.8 Kolte-Patil Developers 20 262 BUY 316 19.4 23.1 22.4 13.5 11.3 11.7 7.8 6.7 6.4 14.1 15.0 13.0 8

Rating Definitions BUY NEUTRAL SELL :Where the stock is expected to deliver more than 10% returns over the next 12 month period :Where the stock is expected to deliver (-) 10% to 10% returns over the next 12 month period :Where the stock is expected to deliver less than (-) 10% returns over the next 12 month period Disclosure: We, Parikshit D Kandpal, CFA & Kunal Bhandari, ACA authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest. Any holding in stock No HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475. Disclaimer: This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments.this report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HSL. Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments. HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business. HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report. HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600 HDFC Securities Limited, SEBI Reg. No.: NSE-INB/F/E 231109431, BSE-INB/F 011109437, AMFI Reg. No. ARN: 13549, PFRDA Reg. No. POP: 04102015, IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657, SEBI Research Analyst Reg. No.: INH000002475, CIN - U67120MH2000PLC152193 Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing. 9

HDFC securities Institutional Equities Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013 Board : +91-22-6171 7330 www.hdfcsec.com 10